Evidence map›Paper›PMID 41723424›Full record

ArticleBMC pulmonary medicine2026

Evaluation of a Particle Enhanced Turbidimetric Immunoassay (PETIA) for detecting calprotectin in sputum samples.

Magnus Förnvik Jonsson, Ulrik Hägglund, My Eltén, Torgny Sunnerhagen, Muna Al-Jammal, Magnus Paulsson

Abstract readEvaluation Study
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Magnus Förnvik JonssonSection for Clinical Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden. magnus.fornvik_jonsson@med.lu.se.
Ulrik HägglundDepartment of Clinical Chemistry and Pharmacology, Skåne University Hospital, Lund, Sweden.
My ElténDepartment of Clinical General Laboratory Medicine, Skåne University Hospital, Malmö, Sweden.
Torgny SunnerhagenDivision of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
Muna Al-JammalDivision of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
Magnus PaulssonDivision of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are characterized by persistent airway inflammation and airflow limitation. Measuring airway inflammation may be of value both in research and clinical practice. Calprotectin, a protein associated with neutrophil activation, serves as a potential biomarker for airway inflammation. This study evaluates the performance of a particle enhanced turbidimetric immunoassay (PETIA) for measuring calprotectin in sputum samples.

methodsThirty sputum samples from unique patients were collected at the Department of Clinical Microbiology in Lund, Sweden and treated with dithiothreitol (DTT) before analysis. Calprotectin levels were measured using a PETIA on an automated turbidimetric analysis system (Atellica CH 930 Analyzer). The 30 samples were analyzed in triplicate the day of sample collection (Day 0), after storage at 4 °C for two to four days (Day 2–4), and after six to seven days (Day 6–7). An additional aliquot from each sample was stored at -20 °C and analyzed after 41 to 58 days (Day 41–58). Precision, accuracy, and stability of the assay were assessed. Precision was evaluated using pooled- and individual sputum samples while accuracy was determined through spiking studies and dilution linearity. Stability was tested by comparing calprotectin levels Day 2–4, Day 6–7 and Day 41–58 with Day 0, respectively. Instability equations were calculated for samples stored at 4 °C and at -20 °C, respectively.

resultsThree different pools were each analyzed 25 times during five days. The coefficient of variation (CV) for the calprotectin concentration was below 3% for all three. Considering precision based on individual samples, 90% of 120 triplicates had a CV below 7%. These figures indicate an acceptable precision. The spiking and dilution studies showed that measured calprotectin concentrations matched expected levels, with deviations below 10%. Calprotectin concentrations Day 2–4, Day 6–7 and Day 41–58 did not significantly differ from Day 0, and the slope of the instability equations did not significantly differ from 0. It implies that calprotectin concentration can be measured in DTT treated sputum stored for up to one week at 4 °C and up to two months at -20 °C.

conclusionThe evaluated PETIA, running on an automated system, provides a promising method for measuring calprotectin in sputum, supporting its potential use in both clinical and research applications.

Indexed as

Cystic FibrosisImmunoturbidimetryLeukocyte L1 Antigen ComplexPulmonary Disease, Chronic ObstructiveSputumAdultBiomarkersFemaleHumansMaleMiddle AgedNephelometry and TurbidimetryReproducibility of ResultsBiomarkersLeukocyte L1 Antigen ComplexAirway inflammationCalprotectinCOPDCystic fibrosisPETIASputumStabilityTurbidimetric

Identifiers

PMID41723424
PMCPMC12930727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.